Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity

Jones, K., Nourse, J., Corbett, G. and Gandhi, M. K. (2010) Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. International Journal of Laboratory Hematology, 32 1p1: e169-e174. doi:10.1111/j.1751-553X.2008.01130.x

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Jones, K.
Nourse, J.
Corbett, G.
Gandhi, M. K.
Title Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity
Journal name International Journal of Laboratory Hematology   Check publisher's open access policy
ISSN 1751-5521
1751-553X
0141-9854
Publication date 2010-02
Year available 2009
Sub-type Article (original research)
DOI 10.1111/j.1751-553X.2008.01130.x
Volume 32
Issue 1p1
Start page e169
End page e174
Total pages 6
Editor Steve Kitchen
Szu-Hee Lee
Place of publication Oxford, U.K.
Publisher Wiley-Blackwell Publishing
Collection year 2011
Language eng
Formatted abstract
Histone deacytelase inhibitiors (HDACi) represent a new class of anti-lymphoma therapeutics. Data in the clinical setting regarding on- and off-target effects of these agents are limited. Epstein–Barr virus (EBV)-positive lymphomas represent a highly defined system in which to make these observations. We present a case of a patient with multiple relapsed EBV-positive Diffuse Large B-cell Lymphoma that was chemo-refractory to anthracylcines, alkylating agents and rituximab. Treatment was commenced with the HDACi sodium valproate (VPA) in combination with the anti-viral nucleoside analogue ganciclovir (GCV). Therapy resulted in detectable cell-free unencapsulated circulating EBV-DNA providing supportive evidence for the first-time that lysis of virus infected lymphoma cells is induced using this therapeutic combination. EBV-specific CD8+ effector T-cell immunity was not impaired by VPA/GCV. Although GCV/VPA was insufficient to induce clinical remission, our data furthers the rationale that more potent HDAC inhibitors such as butyrate or gemcitabine together with GCV, perhaps in combination with chemotherapy, should be further investigated as therapy in relapsed/refractory EBV-positive lymphomas.
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd
Keyword Epstein–Barr virus
Histone deacetylase inhibitor
Ganciclovir
T-cell
Valproate
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 12 JAN 2009.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 15 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 28 Mar 2011, 10:43:32 EST by Debbie Banks on behalf of Medicine - Princess Alexandra Hospital